An association of intrapartum synthetic oxytocin dosing and the odds of developing autism.

This was a retrospective chart review, not a randomised trial or prospective cohort, so it can show association but not cause. The final sample was small: 171 matched pairs, and 20 autism subjects were dropped because no control could be matched. The low, moderate, and high synthetic oxytocin dose groups were arbitrary, because no established dosing categories existed. Data came from ordinary clinical records, not a research database, so some possible confounders were missing or poorly recorded, including detailed family history and socioeconomic status. The lower odds of ASD in non-Caucasian children likely reflects access and diagnosis differences, not a true protective effect. Some positive findings were subgroup results in boys; the overall duration finding was not significant, and girls showed no significant dosing association. The population came from a smaller midwestern city with a large rural area, so results may not generalise broadly.

Do not read this as proof that synthetic oxytocin causes autism. This was a retrospective chart review, not a trial, and the authors state the results cannot be used to imply causality.